Nayzilam (Midazolam) Patent Expiration, LOE Window & CMS Spending

Nayzilam (Midazolam) by Ucb: FDA Orange Book LOE 2028-01-18, 0 AB generics, $115.9M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN211321 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-01-18
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$115.9M
2024 Medicare Part D Spend$36.9M
2024 Medicaid Spend$79.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.